Literature DB >> 31870099

Histone Butyrylation/ Acetylation Remains Unchanged in Triple Negative Breast Cancer Cells after a Long Term Metabolic Reprogramming.

Fatemeh Mehdikhani1, Hossein Ghahremani1, Saeedeh Nabati1, Hanieh Tahmouri1, Majid Sirati-Sabet1, Siamak Salami1.   

Abstract

BACKGROUND: Altered metabolism is one of the hallmarks of the cancer cells which reciprocally interrelate with epigenetic processes, such as post-translational histone modifications to maintain their desired gene expression profiles. The role of beta-hydroxybutyrate as a ketone body in cancer cell biology and histone modifications are reported. The present study aimed to evaluate the impacts of long-term metabolic reprogramming via glucose restriction and beta-hydroxybutyrate treatment on histone acetylation and butyrylation in MDA-MB231 cells as a model of triple negative stem-like breast cancer.
METHODS: For long-term treatment, cells were set up in three groups receiving DMEM with restricted glucose (250 mg/L), DMEM with restricted glucose but enriched with five millimolar beta-hydroxybutyrate and DMEM with standard glucose (1gL) and investigated for a month. Histone modifications, including H3 acetylation and butyrylation, were investigated by immunoblotting after an acid extraction of the histone proteins. RESULTS AND
CONCLUSION: Neither beta-hydroxybutyrate enrichment nor glucose restriction elicited a significant effect on the butyrylation or acetylation level of histone H3 upon a long-term treatment. Metabolic plasticity of cancer cells, mainly stem-like triple negative breast cancer cells alleviate or neutralize the impact of long-term metabolic reprogramming via restriction of glucose and histone modifications enrichment. These results shed new light upon the mechanism of controversial efficacy of ketogenic diets in clinical trials.

Entities:  

Keywords:  beta-hydroxybutyrate; cellular metabolism; histone butyrylation; triple negative breast cancer

Mesh:

Substances:

Year:  2019        PMID: 31870099      PMCID: PMC7173388          DOI: 10.31557/APJCP.2019.20.12.3597

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  39 in total

Review 1.  Histone deacetylation in epigenetics: an attractive target for anticancer therapy.

Authors:  Antonello Mai; Silvio Massa; Dante Rotili; Ilaria Cerbara; Sergio Valente; Riccardo Pezzi; Silvia Simeoni; Rino Ragno
Journal:  Med Res Rev       Date:  2005-05       Impact factor: 12.944

2.  Metabolic Regulation of Gene Expression by Histone Lysine β-Hydroxybutyrylation.

Authors:  Zhongyu Xie; Di Zhang; Dongjun Chung; Zhanyun Tang; He Huang; Lunzhi Dai; Shankang Qi; Jingya Li; Gozde Colak; Yue Chen; Chunmei Xia; Chao Peng; Haibin Ruan; Matt Kirkey; Danli Wang; Lindy M Jensen; Oh Kwang Kwon; Sangkyu Lee; Scott D Pletcher; Minjia Tan; David B Lombard; Kevin P White; Hongyu Zhao; Jia Li; Robert G Roeder; Xiaoyong Yang; Yingming Zhao
Journal:  Mol Cell       Date:  2016-04-21       Impact factor: 17.970

Review 3.  Glucose Metabolism in Cancer and Ischemia: Possible Therapeutic Consequences of the Warburg Effect.

Authors:  Spela Salamon; Eva Podbregar; Peter Kubatka; Dietrich Büsselberg; Martin Caprnda; Radka Opatrilova; Vanda Valentova; Mariusz Adamek; Peter Kruzliak; Matej Podbregar
Journal:  Nutr Cancer       Date:  2017-01-17       Impact factor: 2.900

Review 4.  Cancer metabolism in space and time: Beyond the Warburg effect.

Authors:  Pierre Danhier; Piotr Bański; Valéry L Payen; Debora Grasso; Luigi Ippolito; Pierre Sonveaux; Paolo E Porporato
Journal:  Biochim Biophys Acta Bioenerg       Date:  2017-02-04       Impact factor: 3.991

5.  Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor.

Authors:  Tadahiro Shimazu; Matthew D Hirschey; John Newman; Wenjuan He; Kotaro Shirakawa; Natacha Le Moan; Carrie A Grueter; Hyungwook Lim; Laura R Saunders; Robert D Stevens; Christopher B Newgard; Robert V Farese; Rafael de Cabo; Scott Ulrich; Katerina Akassoglou; Eric Verdin
Journal:  Science       Date:  2012-12-06       Impact factor: 47.728

Review 6.  Ketone bodies as epigenetic modifiers.

Authors:  Hai-Bin Ruan; Peter A Crawford
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2018-07       Impact factor: 4.294

Review 7.  An overview of triple-negative breast cancer.

Authors:  Pankaj Kumar; Rupali Aggarwal
Journal:  Arch Gynecol Obstet       Date:  2015-09-04       Impact factor: 2.344

8.  Ketone body utilization drives tumor growth and metastasis.

Authors:  Ubaldo E Martinez-Outschoorn; Zhao Lin; Diana Whitaker-Menezes; Anthony Howell; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2012-09-19       Impact factor: 4.534

Review 9.  Ketogenic diets as an adjuvant cancer therapy: History and potential mechanism.

Authors:  Bryan G Allen; Sudershan K Bhatia; Carryn M Anderson; Julie M Eichenberger-Gilmore; Zita A Sibenaller; Kranti A Mapuskar; Joshua D Schoenfeld; John M Buatti; Douglas R Spitz; Melissa A Fath
Journal:  Redox Biol       Date:  2014-08-07       Impact factor: 11.799

Review 10.  Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect.

Authors:  Iñigo San-Millán; George A Brooks
Journal:  Carcinogenesis       Date:  2017-02-01       Impact factor: 4.944

View more
  1 in total

1.  Effect of a Ketogenic Diet on Oxidative Posttranslational Protein Modifications and Brain Homogenate Denaturation in the Kindling Model of Epilepsy in Mice.

Authors:  Pavlina Andreeva-Gateva; Zafer Sabit; Dimitar Bakalov; Serkan Sayiner; Radka Tafradjiiska-Hadjiolova; Stella Zaharinova; Silviya Abarova; Rumiana Koynova; Boris Tenchov
Journal:  Neurochem Res       Date:  2022-03-22       Impact factor: 3.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.